熱門資訊> 正文

诺华在舍格伦病晚期试验中取得成功

2025-08-11 21:01

Novartis (NYSE:NVS) said that the two late-stage trials testing its antibody therapy, ianalumab, in adults with Sjögren's disease, met main goal.
The pivotal trials showed statistically significant improvements in disease activity compared to placebo.
In terms of safety, ianalumab was well tolerated and had a favorable safety profile in Sjögren's disease.
The stock is up about 1.6% premarket.

More on Novartis

Novartis AG 2025 Q2 - Results - Earnings Call Presentation
Novartis AG (NVS) Q2 2025 Earnings Call Transcript
Novartis Q2 Earnings Review: Solid Results Justify All-Time High Share Price
SA Asks: How could Trump's drug pricing demands impact stocks?
Avidity Biosciences jumps on report of Novartis takeover approach

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。